Search
Clesrovimab
go.drugbank.com/drugs/DB18877Approved[A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Synonyms: IL-1 TRAP, IL-1-TRAPCategories: Receptors, Interleukin-1 Type IAcemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigationalit kept the same side effects. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSProducts: RASLACOF-XOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.
Clascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. … [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766]
Categories: Anti-Acne Preparations for Topical UsePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
go.drugbank.com/bio_entities/BE0005530TargetHumansInvolved in the regulation of synaptic function in excitatory hippocampal synapses. … May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.
Synonyms: Mutated in multiple advanced cancers 1tRNA-dihydrouridine(20) synthase [NAD(P)+]-like
go.drugbank.com/bio_entities/BE0020091EnzymeHumansSpecifically modifies U20 in cytoplasmic tRNAs (PubMed:38680565). Activity depends on the presence of guanosine at position 19 in the tRNA substrate (PubMed:38680565). … Catalyzes the NADPH-dependent synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs (PubMed:15994936, PubMed:26429968, PubMed:30149704, PubMed:34798057, PubMed:38680565).
Synonyms: Up-regulated in lung cancer protein 8Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. … Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2.
Categories: Bile Salt Export Pump InhibitorsBronopol
go.drugbank.com/drugs/DB13960ApprovedNevertheless, ongoing contemporary re-evaluations of bronopol use in large markets such as Canada now place various compositional and product restrictions on the use of the agent in cosmetic products [ … First synthesized in 1897, bronopol was primarily used as a preservative for pharmaceuticals and was registered in the United States in 1984 for use in industrial bactericides, slimicides and preservatives
Categories: Compounds used in a research, industrial, or household settingNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.